Participating Institutes and Centers (ICs) of the National Institutes of
Health (NIH) invite applications for R01 awards to support Bioengineering
Research Partnerships (BRPs) for basic, applied, and translational multi-
disciplinary research that addresses important biological or medical research
problems. In the context of this program, a partnership is a multi-
disciplinary research team that applies an integrative, systems approach to
develop knowledge and/or methods to prevent, detect, diagnose, or treat
disease or to understand health and behavior. The partnership must include
appropriate bioengineering or allied quantitative sciences in combination
with biomedical and/or clinical components. The Principal Investigator (PI)
also serves as the project manager and must be capable of leading the
proposed effort. A BRP may propose design-directed, developmental,
discovery-driven, or hypothesis-driven research at universities, national
laboratories, medical schools, large or small businesses, or other public and
private entities or combinations of these entities. It is expected that a
BRP will have a well-defined goal or deliverable that will be achieved based
on objective milestones specified in the initial application.
On October 11, 2001, the NIH issued a related program announcement (PA)
PA-02-011 (http://grants.nih.gov/grants/guide/pa-files/PA-02-011.html)
for Bioengineering Research Grants (BRGs). The BRGs differ from the BRPs
in that the research will be performed in a single laboratory, by a single
investigator, or by a small group of investigators. On January 16, 2003, the
NIH issued another related program announcement PA-03-058
(http://grants.nih.gov/grants/guide/pa-files/PA-03-058.html) for
Exploratory/Developmental (R21) Bioengineering Research Grants (EBRG). The
EBRGs differ from the BRPs in that (1) the research will be performed in a
single laboratory, by a single investigator, or by a small group of
investigators and (2) the projects are high-risk/high-payoff in nature (R21
mechanism) as compared to the R01-type grants supported by the BRP program.
Find Funding Opportunities
COVID-19 Funding Notices | Approved Initiative Concepts | Research Opportunity Announcements
All NINDS-related notices of funding opportunities (NOFOs), request for applications (RFAs), program announcements (PAs), and other NIH Guide announcements are listed. Search the Closed Opportunities tab to find expired opportunities. Search the Notices tab to find all Notices.
Learn more about award types and program directors and managers.
NINDS has a number of open positions for researchers and clinicians to contribute to exciting neuroscience programs - APPLY NOW!
For more focused results add quotes to indicate parameters. Example format: "search term".
Expiration Date: Tuesday, May 23, 2006 NOFO Number: PAR-04-023 Release Date: Tuesday, November 18, 2003 Notice Type: PAR
Expiration Date: Thursday, June 9, 2005 NOFO Number: RFA-AI-04-001 Release Date: Monday, November 10, 2003 Notice Type: RFA
The National Institute of Allergy and Infectious Diseases (NIAID), the
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),
the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),
the National Institute of Neurological Disorders and Stroke (NINDS), and the
National Institute of Dental and Craniofacial Research (NIDCR) of the National
Institutes of Health (NIH) invite investigator-initiated research applications
for mechanistic studies in clinical trials of: (1) immunomodulatory
interventions for immune system mediated diseases, including, but not limited
to: asthma and allergic diseases; graft failure in solid organ, cell, tissue
and stem cell transplantation; and chronic inflammatory, autoimmune, and
immunodeficiency diseases; and (2) preventative and therapeutic, vaccines for
non-HIV/AIDS infectious diseases, including NIAID Category A, B, and C agents
of bioterrorism and emerging/re-emerging infectious diseases. This Request for
Applications (RFA) is a continuation and modification of RFA AI-02-003
(http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-02-003.html ).
In order to review and confer awards to grant applications received in
response to this RFA in a timely fashion, without delay of the parent clinical
trial, NIAID has developed a pilot project in collaboration with the NIH
Center for Scientific Review (CSR): NIAID/CSR PILOT OF HYPERACCELERATED
REVIEW/AWARD. All applications responding to this RFA will be subject to this
hyperaccelerated review/award process. Highly meritorious applications
selected for funding under this RFA will receive their awards thirteen weeks
after the application receipt date. Holidays and other circumstances may
alter this schedule slightly.
Expiration Date: Thursday, February 1, 2007 NOFO Number: PAR-04-018 Release Date: Wednesday, November 5, 2003 Notice Type: PAR
The National Institute of Neurological Disorders and Stroke (NINDS) and
the National Institute of Deafness and Other Communication Disorders
(NIDCD) invite qualified investigators to submit grant applications for
the establishment of National Centers for Neurofibromatosis Research.
Recent discoveries have created important opportunities for basic,
translational, and clinical research on the neurofibromatoses. The
purpose of this Program Announcement (PA) is to encourage the formation
and development of research centers that can capitalize on these
opportunities, and ultimately develop therapeutic interventions for
neurofibromatosis patients. These centers are intended to provide
focused expertise and resources, and establish a multi-disciplinary
environment that will accelerate research progress.
Expiration Date: Friday, March 19, 2004 NOFO Number: RFA-DK-03-024 Release Date: Friday, October 24, 2003 Notice Type: RFA
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),
National Institute of Allergy and Infectious Diseases (NIAID), National Eye
Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National
Institute of Neurological Disorders and Stroke (NINDS), and National
Institute of Child Health and Human Development (NICHD) encourage the
scientific community to use proteomics technologies to study type 1 diabetes
(T1D) and its complications. Proteomic technologies have been successfully
used for the identification of cancer biomarkers, for the identification of
novel drug targets and for studying several biological processes relevant to
human health. High throughput metabolic profiling has been recently
implemented for metabolomic studies. However, as of today these technologies
have been applied to study T1D and its complication only in a limited way.
Moreover, currently available proteomic and metabolomic technologies
represent a great opportunity for advancing the field of T1D and its
complications. This RFA intends to promote the use of these technologies to
study T1D and its complications emphasizing the importance of collaborative
efforts between investigators with expertise in proteomics or metabolomics
and investigators with expertise in T1D.
Expiration Date: Tuesday, May 2, 2006 NOFO Number: PA-04-008 Release Date: Thursday, October 16, 2003 Notice Type: PA
The purpose of the NIH Clinical Trial Planning Grant (R34) is to provide
support for the development of a Phase III clinical trial, including the
establishment of the research team, the development of tools for data
management and oversight of the research, the definition of recruitment
strategies, and the finalization of the protocol and other essential elements
of the study included in a manual of operations/procedures. The Clinical
Trial Planning Grant is not designed for the collection of preliminary data
or the conduct of pilot studies to support the rationale for a clinical
trial.
An NIH-defined Phase III clinical trial is a broadly based prospective
clinical investigation, usually involving several hundred or more human
subjects, for the purpose of evaluating an experimental intervention in
comparison with a standard or control intervention or comparing two or more
existing treatments. Often, the aim of such investigation is to provide
evidence leading to a scientific basis for consideration of a change in
health policy or standard of care. The definition includes pharmacologic,
non-pharmacologic, and behavioral interventions for disease prevention,
prophylaxis, diagnosis or therapy. Community- and other population-based
intervention trials also are included.
The planning grant is designed to permit early peer review of the rationale
and design of the proposed clinical trial and to provide support for the
development of a detailed Manual of Procedures (MOP) including all elements
essential to the launching of a trial.
Investigators wishing to apply for an R34 grant should be aware that
individual ICs may have specific requirements for this funding mechanism and,
therefore, should consult IC staff to determine if an application is
appropriate. NIH Offices that participate in this PA (ORWH, OBSSR, ORD, ODS)
are listed but do not have funding authority and must work through an
Institute or Center.
Expiration Date: Tuesday, May 2, 2006 NOFO Number: PA-04-006 Release Date: Wednesday, October 8, 2003 Notice Type: PA
This Program Announcement replaces PA-02-003.
The purpose of this Program Announcement (PA) is to encourage submission of new
research project grant (R01) and exploratory/developmental grant (R21) applications
to research and develop innovative technologies, methodologies, or instrumentation
for basic or clinical studies of the brain or behavior in human or non-human
animals. Also solicited are applications for support to research, develop, and
significantly enhance existing technologies that are important to understanding the
brain or behavior.
Expiration Date: Wednesday, October 26, 2005 NOFO Number: PAR-03-176 Release Date: Wednesday, September 24, 2003 Notice Type: PAR
This Program Announcement (PA) provides updated guidelines for National
Institutes of Health (NIH) support of scientific meetings. It replaces the
previous guidelines issued in the NIH GUIDE on October 30, 1998,
http://grants.nih.gov/grants/guide/notice-files/not98-151.html and is
effective with the December 15th receipt date for cycle III applications. An
NIH Conference Grant Website has been created to centralize information
regarding grants for scientific meetings and conferences, at
http://grants1.nih.gov/grants/funding/r13/index.htm. This site includes
contact information for the participating NIH Institutes and Centers and
Offices and links to detailed information regarding specific interests and
funding parameters. This site and related links is updated frequently and
interested parties should check periodically for the most current information.
A major revision made in this announcement is the requirement that
applications for conference grant support present a letter from the
appropriate NIH Institute/Center (IC) staff documenting advance permission to
submit an R13 or U13 application. As a streamlining measure, there are now
three annual receipt dates for all applications for support of scientific
meetings, and decisions about awards will normally be made within six months
of submission.
Expiration Date: Thursday, November 2, 2006 NOFO Number: PAR-03-174 Release Date: Wednesday, September 17, 2003 Notice Type: PAR
This PAR replaces PAR-01-119.
The NINDS is committed to identifying effective treatments for neurological
disorders by supporting well-executed clinical trials. Before a definitive
clinical trial can be designed, preliminary clinical studies are often
required. The NINDS announces its interest in supporting studies required to
obtain necessary information to establish clearly the clinical basis for
proceeding to a definitive trial. The purpose of the PRELIMINARY
INVESTIGATIONS LEADING TO OPTIMAL TRIALS IN NEUROLOGY grant (for brevity
referred to as NINDS Preliminary Clinical Trials grant) is to obtain
preliminary data and conduct studies to support the rationale for a subsequent
definitive clinical trial of an intervention to treat or prevent neurological
disease.
Expiration Date: Saturday, July 1, 2006 NOFO Number: PAS-03-173 Release Date: Tuesday, September 16, 2003 Notice Type: PAS
The National Institute of Neurological Disorders and Stroke (NINDS), along
with the National Institute of Dental and Craniofacial Research (NIDCR),
invite applications to advance our understanding of the neurobiology of
persistent pain mediated by the trigeminal nerve and to develop effective
therapeutic strategies to alleviate pain associated with disorders of
myofascial, nervous, or skeletal tissues of the head and face, which are
innervated by this nerve. The purpose of this initiative is to foster
research that addresses the mechanisms of pain onset, chronic pain
conditions, and responsiveness to pain therapy through novel basic and
clinical research. Current knowledge of the neurobiology and neurochemistry
of nociception, pain modulation and pain perception needs to be further
developed and correlated with clinical manifestations of craniofacial pain to
improve therapeutic strategies. This Program Announcement with Set-Aside
funds (PAS) contributes to the goals of the NIH Pain Consortium, which is co-
chaired by NINDS, NIDCR, and the National Institute of Nursing Research
(NINR).
Expiration Date: Tuesday, February 1, 2005 NOFO Number: PAS-03-172 Release Date: Tuesday, September 16, 2003 Notice Type: PAS
National Institute of Neurological Disorders and Stroke (NINDS), the National
Institute on Drug Abuse (NIDA), the National Institute of Deafness and Other
Communication Disorders (NIDCD) the National Institute of Alcohol Abuse and
Alcoholism (NIAAA), and the National Institute on Aging (NIA) invite
applications for studies on the cellular and molecular signaling between the
local environment within organisms and stem and progenitor cells that are
either introduced as transplants or are normally resident within host tissues
and organs. The objective of this initiative is to promote a thorough
exploration and characterization of the bi-directional communication between
multipotent cells and the three-dimensional local milieu or niche that they
encounter in vivo under normal and compromised states, such as with aging or
following injury, disease or drug exposure. Of particular interest is the
rigorous characterization of how interactions with localized cues in space
and time regulate stem cell survival, migration, replication and 'plasticity'
in the nervous system and other parts of the body. Projects that address
comparisons between the responses of stem cells within niches in the
developing and mature or aging nervous system in vivo, or in host
microenvironments modified by injury, disease, or by exposure to drugs and
alcohol would also be directly relevant to this Program Announcement with
Set-aside (PAS), as are studies to compare different classes of stem cells or
progeny at progressively more advanced stages of differentiation when placed
in the same sites in vivo.